image: Animals were inoculated intramuscularly with recombinant AAV vectors capable of expressing eCD4-Ig, a very broad HIV entry inhibitor. The vector turns some muscle tissue into a factory for producing eCD4-Ig and secreting it into the blood, where it can prevent infection after multiple, high-dose challenges with two very different HIV-like viruses. This material relates to a paper that appeared in the Jul. 24, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by M.R. Gardner at Scripps Research Institute in Jupiter, FL; and colleagues was titled, "AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges." view more
Credit: Michael Farzan, PhD, The Scripps Research Institute, 2019